1. Home
  2. SOHU vs ADCT Comparison

SOHU vs ADCT Comparison

Compare SOHU & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sohu.com Limited

SOHU

Sohu.com Limited

HOLD

Current Price

$16.37

Market Cap

486.8M

Sector

Technology

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$3.94

Market Cap

484.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOHU
ADCT
Founded
1996
2011
Country
China
Switzerland
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
486.8M
484.4M
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
SOHU
ADCT
Price
$16.37
$3.94
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$20.00
$7.75
AVG Volume (30 Days)
23.9K
757.8K
Earning Date
02-09-2026
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
30.86
EPS
N/A
N/A
Revenue
N/A
$81,357,000.00
Revenue This Year
$1.61
N/A
Revenue Next Year
$3.78
$68.29
P/E Ratio
$1.16
N/A
Revenue Growth
N/A
14.85
52 Week Low
$7.79
$1.05
52 Week High
$17.30
$4.98

Technical Indicators

Market Signals
Indicator
SOHU
ADCT
Relative Strength Index (RSI) 49.58 46.19
Support Level $15.74 $3.79
Resistance Level $17.12 $4.77
Average True Range (ATR) 0.53 0.27
MACD -0.01 -0.06
Stochastic Oscillator 56.70 11.40

Price Performance

Historical Comparison
SOHU
ADCT

About SOHU Sohu.com Limited

Sohu.com Ltd provides online media, games, and search products and services on PCs and mobile devices in China. The company operates in Sohu and Changyou segments. Sohu is an online media content and services provider. Through its social features, Sohu also enables users to generate and distribute content, as well as interact with each other on a platform. Changyou is an online game developer and operator. It generates maximum revenue from the Changyou segment.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: